The global Giant Cell Arteritis Therapeutics Market is experiencing significant growth, driven by an aging population, increased awareness, and advancements in treatment options. Valued at approximately USD 1.1 billion in 2023, the market is projected to reach USD 1.9 billion by 2031, expanding at a CAGR of 6.2% during the forecast period. 

Top 5 Companies with the Largest Market Share

According to Maximize Market Research, the leading companies in the GCA therapeutics market include:

  1. F. Hoffmann-La Roche Ltd.: Roche's Actemra (tocilizumab) is the first FDA-approved therapy specific to GCA, providing a targeted treatment option for patients.

  2. Kiniksa Pharmaceuticals, Ltd.: Kiniksa is actively involved in developing therapies for autoimmune and inflammatory diseases, including GCA. 

  3. AbbVie Inc.: AbbVie's Rinvoq (upadacitinib) recently received FDA approval for the treatment of GCA, marking a significant advancement in oral therapies for the condition. 

  4. Novartis AG: Novartis is engaged in research and development of treatments for various inflammatory conditions, contributing to the GCA therapeutics landscape.

  5. Johnson & Johnson Services, Inc.: Through its Janssen division, Johnson & Johnson is involved in the development of therapies targeting autoimmune diseases, including GCA.

Request Sample Link :   https://www.maximizemarketresearch.com/request-sample/86445/ 

Latest Mergers and Acquisitions

The GCA therapeutics market has witnessed strategic mergers and acquisitions aimed at expanding product portfolios and global reach:

  • In October 2022, Amgen successfully completed the acquisition of ChemoCentryx, enhancing its inflammation and nephrology portfolio with the addition of TAVNEOS (avacopan), a treatment for ANCA-associated vasculitis, a condition related to GCA. 

Recent Developments in the Market

Technological advancements and strategic initiatives are shaping the GCA therapeutics market:

  • In April 2025, the FDA approved Rinvoq (upadacitinib), making it the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults.

  • The European Commission granted marketing approval to Rinvoq for treating GCA, expanding its availability to patients across Europe.

New Funding and Investments

While specific funding rounds have not been publicly disclosed for the leading companies mentioned, the GCA therapeutics market continues to attract significant investments aimed at enhancing technological capabilities and expanding market presence. Companies are investing in research and development to innovate and meet the evolving demands of patients with GCA.

Conclusion

The Giant Cell Arteritis therapeutics market is poised for continued growth, driven by increasing prevalence, advancements in treatment options, and strategic initiatives by leading companies. As the industry evolves, the focus on targeted therapies, patient-centric approaches, and global expansion will remain paramount, offering significant opportunities for both established players and new entrants in the market.